Vitamin D and Vitiligo
Vitiligo is an autoimmune loss of melanocytes causing depigmented skin patches. Vitamin D links to vitiligo on three fronts: topical vitamin D analogues as adjunctive therapy, oral repletion for the frequent underlying deficiency, and narrowband UVB phototherapy which itself raises 25(OH)D.
Deficiency prevalence
Multiple studies find lower mean 25(OH)D in vitiligo patients than controls, and higher rates of deficiency. The 2015 Iranian study by Aghaei found 68% of vitiligo patients had 25(OH)D < 20 ng/mL vs 40% of controls. Vitiligo shares associations with other autoimmune conditions (thyroid disease, alopecia areata) where vitamin D deficiency is also common.
Topical calcipotriene / calcipotriol
Calcipotriene is a synthetic vitamin D analogue. Used alone it produces modest repigmentation in vitiligo, but combining it with narrowband UVB (Kumaran 2006) or topical steroids (Newman 2016) improves repigmentation rates over either alone. Common practice in dermatology for stable, localised vitiligo.
Narrowband UVB (311 nm)
NB-UVB is a first-line phototherapy for generalised vitiligo, with 60–70% of patients achieving at least moderate repigmentation over 6–12 months. It works via direct melanocyte stimulation and immunomodulation — the vitamin D synthesis is a bonus but not the primary mechanism. Some dermatologists check pre-treatment 25(OH)D and supplement deficient patients to potentiate response.
Oral vitamin D supplementation
Small trials of high-dose oral vitamin D (35,000 IU/day for 6 months, Finamor 2013) reported repigmentation in some previously refractory patients. Such doses require calcium monitoring and are not standard care. Correcting deficiency to standard target (≥ 30 ng/mL) is a reasonable adjunct without controversy; going to hypertherapeutic doses is experimental.
Practical guide
- Test 25(OH)D at diagnosis — vitiligo patients frequently deficient.
- Correct to ≥ 30 ng/mL with 2,000–4,000 IU/day cholecalciferol.
- Combine with dermatologist-directed therapy — topical calcipotriene ± steroids, NB-UVB, JAK inhibitors (ruxolitinib cream approved 2022 for vitiligo).
- Do not use high-dose oral vitamin D as a first-line vitiligo therapy without dermatology involvement.